Compare ACM Research Inc (ACMR) vs Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACM Research Inc vs Bio-Rad Laboratories, Inc. Class A Common Stock — how do they compare? ACM Research Inc trades at $95.74 (market cap $6.54B), while Bio-Rad Laboratories, Inc. Class A Common Stock trades at $283.71 (market cap $7.85B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is the larger of the two by market cap, and ACM Research Inc is trading nearer its 52-week high, Bio-Rad Laboratories, Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals.
| ACMR | BIO | |
|---|---|---|
Market Cap | $6.54B | $7.85B |
Sector | Technology | Health |
52-Week High | $126.89 | $339.75 |
52-Week Low | $23.92 | $241.71 |
Enterprise Value | $5.61B | $7.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACMR trades at $98.52, up 0.77% today, with a bullish technical signal from moving averages and a consensus analyst price target of $110. Recent earnings showed a Q1 2026 beat but misses in prior quarters. Revenue grew to $901 million in 2025, though net income margins are under pressure. The stock has experienced volatility, with news highlighting semiconductor sector catalysts and a GF Score of 82 (GuruFocus, June 25, 2026).
Outlook is positive with 80% analyst buy ratings and semiconductor demand tailwinds, but risks include earnings inconsistency, high valuation multiples, and negative operating cash flow. Investors should weigh growth potential against execution risks in a competitive market.
BIO trades at $292.50, down 1.47% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported revenue of $2.58B for 2025 with net income of $759.90M, though it missed EPS estimates for three consecutive quarters. Positive cash flow from operations of $532.20M supports financial health, while recent news highlights Nasdaq compliance and industry participation.
Outlook remains cautiously optimistic with a consensus price target of $305.00, representing ~4% upside. Risks include consistent earnings misses and high P/E of 49.11, but strong analyst buy sentiment (53.85%) and improving profitability margins offer potential for recovery if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACM Research Inc
ACM Research develops and manufactures semiconductor process equipment, specializing in wafer cleaning and electroplating solutions. Its tools are used by global chipmakers to improve productivity and yield for logic and memory chips.
Read more on ACMR →About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →
